Company / FCF Margin
Esperion Therapeutics, Inc. FCF Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-3.3%
FY2025
5-year range
-336.3% / -3.3%
FY2021-FY2025
Trend
+54.9%
vs FY2024
Sector context
#64 of 134
Health Care
What the data says
At -3.3%, Esperion Therapeutics, Inc.'s fcf margin ranks #64 of 134 in the Health Care sector. FCF Margin has increased for 4 consecutive years, from -336.3% in FY2021 to -3.3% in FY2025.
Based on SEC 10-K filings.
-3.3% in FY2025 with a 5-year CAGR of +34.6%.
Improved from -116.5% to -3.3% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +228.4pp
- 5-Year Change
- +34.6pp
- 10-Year Change
- -
Sector benchmark
#64 of 134 in Health CareTop 48% of 134This company -3.3% Sector average -637.8%
▼
+99.5% above sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s fcf margin has grown for 4 consecutive years.
- In FY2025, fcf margin increased 54.9% year-over-year.
- Currently 634.5pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -3.3% | +54.9% |
| FY2024 | -7.2% | +93.8% |
| FY2023 | -116.5% | +49.7% |
| FY2022 | -231.6% | +31.1% |
| FY2021 | -336.3% | -789.4% |
| FY2020 | -37.8% | +21.3% |
| FY2019 | -48.0% | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026